We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register to chat with like-minded investors on our interactive forums.
The current CYC market cap is 167.49M. The company's latest EPS is AUD -0.0500 and P/E is -35.60.
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Revenue | 18.33M | 18.18M | 20.14M | 24.85M | 31.72M |
| Operating Income | -2.33M | -4.99M | -4.52M | -6M | -4.65M |
| Net Income | -2.91M | -6.04M | -5.04M | -6.61M | -4.7M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Total Assets | 32.53M | 28.28M | 55.74M | 49.54M | 45.91M |
| Total Liabilities | 9.32M | 11.16M | 12.67M | 13.01M | 13.66M |
| Total Equity | 23.2M | 17.12M | 43.07M | 36.54M | 32.26M |
| Year End 31 December 2023 | 2019 | 2020 | 2021 | 2022 | 2023 |
|---|---|---|---|---|---|
| AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | AUD (AUD) | |
| Operating | -489k | -8.94M | -1.63M | -6.66M | -7.2M |
| Investing | -820k | -874k | -1.16M | -1.55M | -508k |
| Financing | 8.09M | -986k | 30.17M | -726k | -1.02M |
| Market Cap | 167.49M |
| Price to Earnings Ratio | -35.60 |
| Price to Sales Ratio | 5.28 |
| Price to Cash Ratio | 14.29 |
| Price to Book Ratio | 5.19 |
| Dividend Yield | - |
| Shares Outstanding | 94.1M |
| Average Volume (1 week) | 8.15k |
| Average Volume (1 Month) | 8.31k |
| 52 Week Change | -15.24% |
| 52 Week High | 3.15 |
| 52 Week Low | 1.715 |
| Spread (Intraday) | 0.05 (2.5%) |
| Company Name | Cyclopharm Limited |
| Address |
unit 4 sydney, new south wales 2208 |
| Website | https://www.cyclopharm.com |
| Industry | electromedical apparatus (3845) |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
